PDCD1 and endometrial cancer: The anti–PD-1 toliparimab, in combination with standard megestrol acetate, will be evaluated as a fertility-sparing treatment for patients with stage I endometrioid grade 1 or 2 endometrial cancer who wish to preserve fertility (NCT04046185) [40].